South America Pharmaceutical Packaging Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

South America Pharmaceutical Packaging Market Trends and Insights

Expansion of Pharmaceutical Manufacturing in Brazil and Argentina

Brazil and Argentina are expanding pharmaceutical production capacity, thereby supporting demand for primary and secondary packaging across multiple drug categories. Brazilian generic drug manufacturers sold billions of units in 2025, a significant increase over 2024, with domestic laboratories accounting for most of the generic unit volume. Public procurement under Brazil’s Unified Health System favors individually blister-packed doses for hypertension and diabetes treatments rather than bulk bottles. This requirement supports demand for blister packaging, even for established generic molecules. BNDES approved BRL 650 million (USD 111 million) in financing for Bionovis in 2025, supporting domestic biologics production and future demand for high-complexity injectable packaging.^{[1]Ministério da Saúde, “Em Visita à Bionovis, Presidente Lula e Ministro Padilha Destacam Fortalecimento da Indústria Para Produção de Medicamentos Para o SUS,” Ministério da Saúde, gov.br.}

Rising Chronic Disease and Generic Drug Volumes

Chronic disease treatment creates a stable volume base for oral-solid generic packaging across South America. Losartan, enalapril, atenolol, and amlodipine were among the leading generic products in Brazil during 2025. Losartan recorded 56.4 million boxes sold through April 2025. Retail pharmacies in the region commonly use strip packs and unit-dose blisters for these medicines. This preference increases demand for aluminum foil laminates and printed packaging rather than bulk-bottle formats. It also supports recurring production runs for high-volume medicines that are dispensed over long treatment periods. Generic volume does not necessarily reduce packaging requirements. Unit-dose specifications and traceability rules can increase packaging content per medicine even as active ingredient costs decline.

Growth of Biologics, Vaccines, and Parenteral Therapies

Parenteral drug pipelines are changing primary packaging specifications toward high-integrity containment systems. ANVISA authorized Ranivisio, Brazil’s first biosimilar ranibizumab, in June 2025.^{[2]Agência Nacional de Vigilância Sanitária, “Anvisa Aprova Primeiro Biossimilar de Ranibizumabe no Brasil,” ANVISA, gov.br.} Blau Farmacêutica received ANVISA Good Manufacturing Practice approval for a locally developed pembrolizumab biosimilar in January 2026. These products require packaging that can maintain sterility and protect sensitive formulations. Type I borosilicate glass vials and prefilled syringe systems are used where extractables and leachables performance must be evaluated. Each additional biologic program increases the need for validated glass and rubber closures and controlled-filling components. SCHOTT Pharma, Gerresheimer, and Stevanato Group formed the Alliance for RTU in 2024 to standardize ready-to-use vials and cartridges.^{[3]Stevanato Group, “Stevanato Group, Gerresheimer, and SCHOTT Pharma Announce Strategic Industry Alliance for RTU,” Stevanato Group, ir.stevanatogroup.com.} The initiative is intended to reduce qualification effort and enable faster access to ready-to-use containment systems. This approach is relevant for contract development and manufacturing organizations that need to establish new fill-finish programs on compressed schedules.

Sustainability-Led Shift Toward Recyclable Packaging

Chile’s Extended Producer Responsibility Law No. 20.920 has made the country a leading regional market for sustainable pharmaceutical packaging requirements. Mandatory collection and recovery targets under Supreme Decree DS 12/2020 have been in effect since 2023. The SISREP reporting system, which will be operational from 2025, requires producers and importers to record packaging recovery performance. Pharmaceutical companies selling in Chile must therefore consider end-of-life evidence alongside print quality and drug-contact compliance. This places greater emphasis on the selection of recyclable materials, recovered-content credentials, and clear documentation. The policy can favor secondary packaging suppliers that can meet both pharmaceutical and recovery-related requirements. Suzano offers Pharma Plus paperboard for pharmaceutical outer cartons and blister cards. Global converters are also developing mono-material blister laminates that aim to retain moisture and oxygen-barrier properties while supporting circularity targets.

Volatility in Imported Resin, Aluminum, and Pharmaceutical Glass Costs

Raw material cost volatility is a major operational challenge for pharmaceutical packaging converters in South America. More than 70% of high-purity borosilicate glass tubing used in Brazil is imported. Import tariffs on pharmaceutical glass containers under NCM code 7010 range from 12% to 18%. A 10% depreciation of the Brazilian real can raise landed glass container costs by 5% to 8% in the absence of an offsetting mechanism. Aluminum prices on the London Metal Exchange moved by ±30% between 2023 and 2025. These movements required blister-foil converters to renegotiate contracts with pharmaceutical buyers that may use multiyear fixed supply agreements. Capacity constraints add to this cost exposure. Borosilicate tubing forming lines require 18 to 24 months of lead time from European and Japanese capital equipment suppliers. Producers cannot quickly adjust supply when price changes alter demand.

High Validation Costs for Sterile and Barrier Packaging

Changes to a sterile injectable package can trigger extensive validation work. A new glass type, elastomeric stopper formulation, or barrier-film supplier may require extractables and leachables studies and a variation filing with ANVISA or ANMAT. These validation cycles cost USD 0.5 million to USD 2 million per primary component and take 12 to 24 months to complete. The expense can keep pharmaceutical manufacturers with incumbent suppliers even when other suppliers offer lower prices. This creates a durable barrier for new regional converters trying to enter sterile packaging tenders. It also limits the speed at which buyers can respond to changes in input costs. ISO 15747 requirements for plastic containers used in intravenous injections and ANVISA good manufacturing practice expectations reinforce this barrier. Suppliers must maintain technical documentation and quality systems that support the drug manufacturer’s filing and validation process. Smaller converters often lack the documented testing history needed to compete for validated sterile applications.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Material: Plastics Lead Volume While Paperboard Accelerates Through Sustainability Requirements

Plastics held 48.62% of the South America pharmaceutical packaging market in 2025. HDPE bottles and PET containers support oral-solid generic medicines, while LDPE and LLDPE pouches and tubes serve liquid and semi-solid formulations. Glass carries greater revenue weight than its volume share because Type I borosilicate formats for biologics and vaccines carry a premium. Metal, biopolymers, and other materials address specialized needs, including aluminum foil for blister lidding. The use of biopolymers remains limited by the availability of validated pharmaceutical-grade alternatives.

Paper and paperboard is projected to expand at a 7.45% CAGR from 2026 to 2031, making it the fastest-growing material category. Chilean recovery rules and sustainability programs in Brazil are influencing demand for recyclable cartons and blister cards. Suzano’s Pharma Plus paperboard was designed for pharmaceutical outer cartons and blister-card uses. Klöckner Pentaplast and Constantia Flexibles are developing mono-material blister laminates that retain moisture- and oxygen-barrier performance while supporting recyclable packaging goals. The South America pharmaceutical packaging industry must balance sustainability requirements with drug protection and regulatory documentation.

By Packaging Level: Primary Packaging Holds the Largest Value Position and the Highest Forecast Rate

Primary packaging accounted for 74.62% of the South America pharmaceutical packaging market size in 2025. It is projected to expand at a 7.78% CAGR through 2031, the highest rate among packaging levels. The segment includes containers and closure systems that directly protect medicines, with its value position reflecting the needs of injectables, biologics, and vaccines. Prefilled syringes are the fastest-growing primary format as manufacturers shift from vial-and-syringe systems to ready-to-use configurations. Vials and ampoules still handle the largest volumes for parenteral antibiotics and vaccines.

SCHOTT Pharma’s Itupeva facility in Brazil marked its 25th anniversary in 2026 and employs 500 people. The site produces ampoules, vials, and cartridges for the local market. Secondary packaging includes cartons, sleeves, labels, and inserts, while tertiary formats include corrugated shippers and pallets. ANVISA’s RDC 885/2024 digital leaflet pilot requires changes to secondary cartons so they can carry compliant 2D DataMatrix codes for the regulatory information electronic repository. Cold-chain distribution for biosimilars and vaccines increases the need for coordinated primary, secondary, and tertiary solutions.

By Product Type: Bottles Remain the Largest Format While Prefilled Syringes Gain Value

Bottles were the largest product type in 2025, holding 28.63% of the market value. HDPE and PET bottles are widely used for oral-solid generic medicines and are expected to remain the largest format, although faster blister-pack and syringe demand may reduce their share. Prefilled syringes are projected to expand at an 8.03% CAGR from 2026 to 2031, supported by GLP-1 receptor agonist volumes and local fill-finish investment. Novo Nordisk is upgrading its Montes Claros facility in Brazil with a BRL 6.4 billion investment (USD 1.09 billion) to produce aseptic GLP-1 receptor agonists. Operations are expected to begin in 2028.

The Alliance for RTU standardizes ready-to-use syringe platforms that regional contract development and manufacturing organizations can procure to expand their lines. Vials and ampoules are used for parenteral antibiotics, vaccines, and lyophilized biologics that require the integrity of Type I borosilicate glass. Blister packs remain the principal unit-dose oral dispensing format, while caps and closures provide child-resistant and tamper-evident features for prescription medicines. AptarGroup acquired Sommaplast in December 2025, a São Paulo provider of oral-dosing closures, droppers, dispensers, and dosing cups with more than 400 employees. The transaction reflects the importance of dispensing precision and device-adjacent packaging in the South America pharmaceutical packaging market.

By End User: Pharmaceutical Companies Lead Demand While Integrated Manufacturers Expand Quickly

Pharmaceutical companies accounted for 64.72% of the South America pharmaceutical packaging market in 2025. Brazilian domestic laboratories sold significant billions of generic units and accounted for most of the country’s total generic volume in 2025. They purchase packaging for high-volume oral treatments and prescription products with stricter containment requirements. This demand supports bottles, blisters, cartons, labels, closures, and consistent regulatory compliance in supplier selection.

Pharma manufacturing companies with integrated fill-finish operations are projected to expand at a 7.89% CAGR from 2026 to 2031. They are internalizing packaging procurement as they commission aseptic production lines and retain more value previously held by contract development and manufacturing organizations. These organizations are closely linked to biosimilar and small-molecule generic filings, and their serialization-capable secondary lines depend on higher filling volumes. Research institutes create a smaller demand for clinical-trial vials, syringes, and specialized closures. ANVISA’s regulatory modernization supports Brazil’s clinical trial infrastructure and the need for controlled primary packaging components.

Geography Analysis

Brazil held 52.84% of the South America pharmaceutical packaging market in 2025. Its leading position reflects the scale of its pharmaceutical sector, the largest on the continent and the 7th globally, and the depth of ANVISA requirements. ANVISA’s SNCM framework requires pharmaceutical traceability through serialized DataMatrix barcodes. Consulta Dirigida No. 5/2026 implements the RDC 885/2024 digital leaflet pilot and is prompting secondary-carton redesigns with compliant QR codes. Brazil remains the principal regional demand center for generic medicine packaging and higher-specification injectable formats.

Chile is projected to expand at an 8.12% CAGR from 2026 to 2031, the highest rate among countries in the region. The Chilean segment of the South America pharmaceutical packaging market is supported by Extended Producer Responsibility compliance and greater access to biologics. Companies selling pharmaceutical products in Chile must demonstrate packaging recovery results or finance collective management systems under DS 12/2020. This increases the cost of nonrecyclable secondary packaging and favors paperboard and mono-material formats. Colombia and Peru are mid-tier markets where public health coverage and biosimilar procurement support demand for injectable vials, ampoules, and chronic-disease blister packs.

The Rest of South America category includes Ecuador, Uruguay, Bolivia, Paraguay, and Venezuela. It represents the smallest demand pool, but Ecuador and Uruguay offer accessible opportunities through stable regulatory settings and expanding private pharmaceutical activity. Bolivia and Venezuela remain constrained by infrastructure gaps and cold-chain limitations beyond major cities. The South America pharmaceutical packaging market combines a large Brazilian demand base with a faster-moving Chilean market and diverse smaller-country opportunities.